AstraZeneca CEO says Summit's cancer drug will drive next-gen combination treatments
- Summit: 5 events in the last 90 days
- Previous: earlier the same day · AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
What happened
Pascal Soriot told CNBC that ivonescimab could combine with antibody-drug conjugates to treat tumors that existing immunotherapies handle less well
Summary assembled by rule from the sources below